Russia has announced that its experimental cancer vaccine, Enteromix, has successfully completed preclinical trials, raising cautious optimism about new treatment possibilities for one of the world’s deadliest diseases.
Veronika Skvortsova, head of the Russian Federal Medical-Biological Agency (FMBA), told delegates at the Eastern Economic Forum in Vladivostok that the vaccine is “now ready for use,” subject to official approval.
She said that years of research, including three years of mandatory preclinical testing, demonstrated tumour reductions of 60 to 80 per cent depending on the cancer type, as well as improved survival rates among test subjects.
Initial focus on colorectal cancer
According to reports, the vaccine is primarily designed to target colorectal cancer, but researchers are also developing versions for glioblastoma—a highly aggressive brain cancer—as well as melanomas, including rare ocular melanoma.
Some outlets reported that the vaccine achieved 100% efficacy in trials, though Newsweek noted that it was unable to verify this claim.
The FMBA has not yet announced a timeline for human trials or widespread availability, but Skvortsova’s comments suggest Russia may soon seek regulatory approval.
